The Food and Drug Administration issued a warning in 2012 about cases of apparent short-term cognitive impairment with statin use, while acknowledging that the cardiovascular benefits outweigh the risks. However, according to a new study, published in the Journal of the American College of Cardiology in recent days, the use of statin therapy in adults aged 65 and over does not seem to be associated with incident dementia, mild cognitive impairment or decline in individual cognitive domains.
Cognitive decline and dementia
Cognitive decline and dementia are major health problems in older people, affecting about 10% of people over the age of 60. Statins are used to reduce low-density lipoprotein cholesterol and are a key treatment for the prevention of primary cardiovascular disease. The Food and Drug Administration with its alert had raised fears of a limitation on the use of statins. On the other hand, some systematic reviews had shown insufficient evidence on the impact of statins on the cognitive domain, while some research had shown conflicting results, with some showing a neurocognitive benefit of statins and others reporting a null effect.
According to the authors of this new study, considering that statins are used extensively among the elderly, and their use is expected to further increase in the future, determining the effects of statin therapy on cognition in the elderly is critical in helping physicians assess their benefits versus the associated risks. “With statins being increasingly prescribed to older adults, their potential long-term effects on cognitive decline and dementia risk have attracted growing interest,” said Zhen Zhou, PhD, Menzies Institute for Medical Research at the University of Tasmania in Australia and lead author of the study. “The present study adds to previous research by suggesting that statin use at baseline was not associated with subsequent dementia incidence and long-term cognitive decline in older adults.”
The ASPREE trial
Researchers of this study analyzed data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial. ASPREE was a large prospective, randomized placebo-controlled trial of daily low-dose aspirin, which included 19,114 participants 65 years old or older with no prior CVD event, dementia or major physical disability, between 2010 and 2014 from Australia and the U.S. One of the key selection criteria of ASPREE was that participants had to have a score of ≥78 for the Modified Mini-Mental State Examination test, a screening test for cognitive abilities, at enrollment.
Researchers excluded participants with missing values for cognitive test scores and/or covariates at baseline, resulting in 18,846 participants. They were grouped by their baseline statin use versus non-statin use, with 5,898 (31.3%) of participants taking statins. The study aimed to measure outcomes including incident dementia and its subclassifications (probable Alzheimer’s disease, mixed presentations); mild cognitive impairment and its subclassifications (mild cognitive impairment consistent with AD, other forms); changes in domain-specific cognition including global cognition, memory, language and executive function, and psychomotor speed; and in the composite of these domains.
Incident cases of dementia
After a median of 4.7 years of follow-up, researchers found 566 incident cases of dementia (including probable Alzheimer’s disease and mixed presentations). Compared with no statin use, statin use was not associated with risk of all-cause dementia, probable Alzheimer’s disease or mixed presentations of dementia. There were 380 incident cases of mild cognitive impairment found (including mild cognitive impairment consistent with Alzheimer’s disease and other forms. Compared to no statin use, statin use was not associated with risk of mild cognitive impairment, mild cognitive impairment consistent with Alzheimer’s disease or other forms of mild cognitive impairment. There was no statistically significant difference in the change of composite cognition and any individual cognitive domains between statin users versus non-statin users. Also, no significant differences were found in any of the outcomes of interest between users of hydrophilic and lipophilic statins. However, researchers did find interaction effects between baseline cognitive ability and statin therapy for all dementia outcomes.
According to the researchers, this study has several limitations, including observational study bias, lack of data on the length of prior use of statins and the dose of statins was not recorded in the ASPREE trial, so their effects could not be fully explored. Researchers conclude the study must be interpreted with caution and will require confirmation by randomized clinical trials designed to explore the neurocognitive effects of statins in older populations.
The editorial comment
In an accompanying editorial comment, Christie M. Ballantyne, MD, professor at Baylor College of Medicine in Houston, said the study does have limitations that the authors address, but agreed the findings suggest statins do not contribute to cognitive decline.
“Overall, the analysis was well done, and its main strengths are a large cohort with a battery of standardized tests that allowed the investigators to track both cognition and incidence of dementia and its subtypes over time,” Ballantyne said. “Lingering questions such as the one raised by this analysis regarding potential adverse effects of statins in individuals with mildly impaired cognition can only be answered in randomized controlled trials in the appropriate age group and population and with appropriate testing and adequate follow-up. In the meantime, practicing clinicians can have confidence and share with their patients that short-term lipid lowering therapy in older individuals, including with statins, is unlikely to have a major impact on cognition”.
This post is also available in: Chinese (Simplified)